HOW WELL DOES ULTRASOUND-ASSESSED SYNOVITIS IN REDUCED JOINT SETS PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS? - EXPLORATORY RESULTS FROM A PHASE 3B STUDY

被引：0

作者：

D'agostino, M. A. ^{[1
]}

Conaghan, P. G. ^{[2
]}

Gaillez, C. ^{[3
]}

Naredo, E. ^{[4
]}

Mandl, P. ^{[5
]}

Carron, P. ^{[6
]}

Senolt, L. ^{[7
,8
]}

Rosa, J. ^{[9
]}

Lopez-Rodriguez, A. ^{[10
]}

Goyanka, P. ^{[11
]}

Sahoo, B. G. ^{[12
]}

Bao, W. ^{[13
]}

Schett, G. ^{[14
]}

Boers, M. ^{[15
]}

机构：

[1] Univ Cattolica Sacro Cuore, Rheumatol, Rome, Italy

[2] Univ Leeds, Rheumatol, London, England

[3] Novartis Pharma AG, Immunol & Rheumatol, Basel, Switzerland

[4] Hosp Fdn Jimenez Diaz & Autonoma Univ, Dept Rheumatol & Joint & Bone Res Unit, Madrid, Spain

[5] Med Univ Vienna, Div Rheumatol, Vienna, Austria

[6] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium

[7] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic

[8] Charles Univ Prague, Dept Rheumatol, Prague, Czech Republic

[9] Hosp Italiano Buenos Aires & Univ Inst, Rheumatol Unit, Internal Med Serv, Buenos Aires, DF, Argentina

[10] PSOAPS Psoriasis Clin & Res Ctr, Dermatol Country, Guadalajara, Mexico

[11] Novartis Healthcare Pvt Ltd, Clin Project Management, Hyderabad, India

[12] Novartis Healthcare Pvt Ltd, Biostat, Hyderabad, India

[13] Novartis Pharmaceut, Biostat, East Hanover, NH USA

[14] FAU Erlangen Nurnberg & Univ Klinikum Erlangen, Dept Internal Med 3, Erlangen, Germany

[15] Vrije Univ, Amsterdam UMC, Dept Epidemiol & Data Sci, Amsterdam, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Psoriatic arthritis; bDMARD;

D O I：

10.1136/annrheumdis-2023-eular.2548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0225

引用

页码：340 / 341

页数：2

共 50 条

[21] Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs
Besuyen, R.
Genovese, M.
de Vlam, K.
Gottenberg, J. E.
Kalunian, K.
Bartok, B.
Tan, Y.
Guo, Y.
Tasset, C.
Sundy, J.
Walker, D.
Takeuchi, T.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S350 - S352
[22] EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
Coates, Laura C.
Gossec, Laure
Theander, Elke
Bergmans, Paul
Neuhold, Marlies
Karyekar, Chetan S.
Shawi, May
Noel, Wim
Schett, Georg
McInnes, Iain B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S106 - S107
[23] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study
Genovese, Mark
Helliwell, Philip
Combe, Bernard
Kremer, Joel
Adams, David
Lee, Chin
Kerr, Lisa
Nash, Peter
Rahman, Proton
JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 996 - 996
[24] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Genovese, M. C.
Combe, B.
Kremer, J.
Adams, D. H.
Lee, C.
Kerr, L.
Nash, P.
Garcia, E. G.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S158 - S158
[25] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Genovese, Mark C.
Combe, Bernard
Kremer, Joel
Adams, David
Lee, Chin
Kerr, Lisa
Nash, Peter
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[26] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Genovese, M. G.
Combe, B.
Kremer, J.
Adams, D.
Lee', C.
Kerr, L.
Nash, P.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1035 - 1036
[27] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo-Controlled, Phase 3 Trial
Mease, Philip J.
Hall, Stephen
FitzGerald, Oliver
van der Heijde, Desiree
Merola, Joseph F.
Avila-Zapata, Francisco
Cieslak, Dorata
Graham, Daniela
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[28] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Strand, Vibeke
Mease, Philip
Soriano, Enrique
Kishimoto, Mitsumasa
Salvarani, Carlo
Damjanov, Nemanja
Anderson, Jaclyn K.
Blondell, Erin
Zueger, Patrick
Saffore, Christopher
Gladman, Dafna
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[29] Improvement in Patient-Reported Outcomes in Patients With Psoriatic Arthritis With Inadequate Response to Non-Biologic DMARDs Treated With Upadacitinib Versus Placebo or Adalimumab: Results From a Phase 3 Study
Gladman, Dafna
Mease, Philip
Soriano, Enrique
Kishimoto, Mitsumasa
Salvarani, Carlo
Damjanov, Nemanja
Anderson, Jaclyn
Blondell, Erin
Zueger, Patrick
Saffore, Christopher
Strand, Vibeke
JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1168 - 1168
[30] SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM PHASE 3 FUTURE-2 STUDY
Mease, P.
Coates, L. C.
Kirkham, B.
McLeod, L. D.
Mpofu, S.
Karyekar, C.
Gandhi, K.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 777 - 778

← 1 2 3 4 5 →